Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is a leader in the growing biologics market, with a strong track record and established relationships in the wound care, burn, surgical, sports medicine, and orthopedics sectors. Despite recent challenges in the reimbursement landscape, the company is well-positioned for long-term success with its best-in-class suite of clinical data, vertically integrated manufacturing infrastructure, and established sales force. The company's recent cost reduction initiatives and leadership salary reductions demonstrate a commitment to maximizing growth opportunities and streamlining operations, leading to a positive outlook for the future.

Bears say

MiMedx Group is facing significant challenges in the current market, as evidenced by its recent cost-cutting measures and lower than expected sales performance. The company's reliance on tissue donorship and the stringent regulations for its products present significant risks to its supply chain and competitive landscape. Additionally, the concentration of revenue from GPOs and IDNs leaves the company vulnerable to potential contract terminations or expirations. These factors, combined with the slow recovery of the wound market, make it difficult for MiMedx to achieve sustainable growth in the future.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.